13312amend03.doc

AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT

1. CONTRACT ID CODE

PAGE OF PAGES

2. AMENDMENT/MODIFICATION NO.

00003

3. EFFECTIVE DATE

04/07/2011

4. REQUISITION/PURCHASE REQ. NO.

5. PROJECT NO. (If applicable)

FORMTEXT

Centers for Disease Control and Prevention (PGO)

Building & Facilities Contracts Branch

2920 Brandywine Road, MS-K71

Atlanta, GA 30341-5539

Centers for Disease Control and Prevention (PGO)

Building & Facilities Contracts Branch

2920 Brandywine Road, MS-K71

Atlanta, GA 30341-5539

8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code)

X

9A. AMENDMENT OF SOLICITATION NO.

2011-N-13312 9B. DATED (See Item 11) 03/23/2011

10A. MODIFICATION OF CONTRACT/ORDER NO.

10B. DATED (See Item 13)

11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS

Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended, by one of the following methods:

(a) By completing Items 8 and 15, and returning submitted; or (c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEGMENT

TO BE RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT

IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

N/A

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS,

IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

A.

THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN

THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).

THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

D.

OTHER (Specify type of modification and authority)

E. IMPORTANT: Contractor is not, is required to sign this document and return copies to the issuing office.

14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)

The purpose of this modification is to:

a) Provide answers to additional questions (#11-18)received after the deadline.

b) The due date of proposals remains at 2:00 p.m. EST Apri1 18, 2011.

Except as provided herein, all terms and conditions of the document referenced in Item 9A or 10A, as heretofore changed, remains unchanged and in full force and effect.

15A. NAME AND TITLE OF SIGNER (Type or print)

16A. NAME OF CONTRACTING OFFICER

Christine N Godfrey

15B. CONTRACTOR/OFFEROR

(Signature of person authorized to sign)

15C. DATE SIGNED

16B. UNITED STATES OF AMERICA

BY ___________________________________________

(Signature of Contracting Officer)

16C. DATE SIGNED

NSN 7540-01-152-8070

STANDARD FORM 30 (REV. 10-83)

PREVIOUS EDITION UNUSABLE

30-105 Prescribed by GSA

FAR (48 CFR) 53.243

Pharmaceutical Transaction Data and Data Services

Solicitation Number: 2011-N-13312

Questions and Answers:

1- Is this a new requirement?

Yes.

2- Is there is an Incumbent to this opportunity. No, this is a new requirement.

If so, could you please provide the following information:

Contractor: N/A Contract Number: N/A Award Date: N/A Expiration Date: N/A Value: N/A

3- Does the vendor have to have a GSA Schedule?

No, this opportunity is not limited to GSA or other GWAC contract holders.

4- Evaluation criteria (page 10) “Relevant or Similar Experience from at least Two Projects” - If the “Offerors” identified in this section consists of a multiple firm team, will CDC evaluate the relative experience of the combined team?

An offeror comprised of a multiple firm team should endeavor to represent the prior experience upon similar accomplished work for each team member (or firm) in the most concise and contextualized manner.

5- Can you describe the % of pharmaceutical transactions that this announcement is seeking to acquire?

Data provided needs to be well characterized in terms of venue of service and context (retail chain pharmacy, retail independent pharmacy, governmental, institutional, etc) and demonstrate representation of ~ 60% of pharmaceutical dispensing locations and ~ 60% of annual pharmaceutical transactions in the U.S. (ideally, this RFP seeks >70% representation of such transactions and coverage).

6- Is there guidance in terms of HIPAA and Public Health for data that may contain PHI / PII?

Yes. The following resources provide clarification regarding PHI / PII and the HIPAA Privacy rule in terms of Public Health Surveillance:

http://www.cdc.gov/mmwr/preview/mmwrhtml/su5201a1.htm http://www.ncbi.nlm.nih.gov/pubmed/12741579 http://www.hhs.gov/ocr/privacy/hipaa/understanding/special/publichealth/index.html 7- Can a clarification of the term “chronic disease treatment / maintenance drugs” be provided?

This broad grouping could include (but not limited to) the following drug classes for medications used in the treatment of chronic diseases such as diabetes, hypertension, hypercholesterolemia, CVD, asthma, etc.:

8- Is the acquisition open to large businesses, since the RFP lists it as "unrestricted" on p. 1, but has FAR 52.219-6 Notice of Total Small Business Set Aside checked on p. 32.? Yes, this requirement is unrestricted. Page 32 has been updated as it was selected incorrectly.

9- The amendment 01 dated March 24, 2011 served to update the title of the notice due to typographical error.

10- The due date for proposals has been extended through 2:00 p.m., EST, April 18, 2011.

11- Is this project part of the BioSense program redesign?

This solicitation and project is housed within the same Program Office (OSELS/ PHSPO) as the BioSense program, but not an integrated component to the current application.

12- In addition to sharing data with state and local public health departments, will CDC also share with other federal agencies? And, if so, which agencies?

13- There are no current plans to share data beyond the CDC to other Federal Agencies. The CDC regularly shares analytic results and reports across a wide range of governmental entities in the course of completing its mission.

14- Is there more time sensitivity around some types of medications rather than others? (e.g., anti-infectives vs. psychotropics?)

Potentially, it is preferred for the time delay, in terms of delivery, to be standardized across all drug classes to facilitate data processing, data CQ efforts, and associated ETL activities.

15- What type of epidemiological analysis will they be conducting? Does it differ by drug class?

Analytic services are not currently part of this specified scope of work. Internal analytic efforts will vary disease / condition, space, time, and drug class.

16- Are data needs different for different drug classes? (e.g., for anti-infectives, prescribing habits and real-time data are more important elements than 3rd party coverage?)

No, at this time, the “data needs” are consistent across all drug classes.

17- How critical is 70% national coverage? Is 40% acceptable? Is a regional approach acceptable (identify areas where we have 70% coverage and offer the service only there)?.

A regional approach to coverage could be reasonable solution for a respondent with limited data assets or coverage. All viable responses which well qualify and describe the nature, distribution, and coverage (by local geography, pharmacy class, population, etc) of pharmaceutical transaction data will be reviewed and considered.

18- How critical is the pick-up/dispensed factor? Would you accept a solution that includes real-time electronic prescription information knowing that it may not necessarily be picked-up by the patient?

This solicitation is interested in elucidating both ordering behaviors and whether a prescription is actually filled / dispensed. Describing the limitations of any given data source is useful. Each response will be reviewed in terms of the stated evaluation criteria with a focus upon identifying the respondent that is most capable of delivering the requirements within the contract period.

19- Why does data need to be delivered within 4 hours? (e.g., why not 3 or 5?)

The 4 hour delivery window was identified as it is technically feasible and aligns with current programmatic needs. This solicitation seeks to ensure that the selected respondent has the technical knowledge and capacity to scale up to this level of performance if needed.

ITEM 10A.